专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07294336B2 Stabilized liquid anti-RSV antibody formulations 有权
标题翻译：稳定液体抗RSV抗体制剂
公开(公告)号：US07294336B2
公开(公告)日：2007-11-13
申请号：US11362267
申请日：2006-02-24
申请人： Cynthia N. Oliver , Erica Shane , Benjamin S. Isaacs , Christian B. Allan , Stephen T. Chang
发明人： Cynthia N. Oliver , Erica Shane , Benjamin S. Isaacs , Christian B. Allan , Stephen T. Chang
IPC分类号： A61K39/395 , A61K39/42
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译：本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，以及很少甚至没有损失 SYNAGIS或其抗原结合片段的生物活性，甚至在长时间的储存期间。特别地，本发明提供了SYNAGIS或其抗原结合片段的液体制剂，其免疫特异性结合RSV抗原，该制剂基本上不含表面活性剂，无机盐和/或其它常见赋形剂。此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。

2. 发明申请

US20120321616A1 STABILIZED LIQUID ANTI-RSV ANTIBODY FORMULATIONS 有权
标题翻译：稳定液体抗RSV抗体制剂
公开(公告)号：US20120321616A1
公开(公告)日：2012-12-20
申请号：US13481640
申请日：2012-05-25
申请人： Cynthia N. OLIVER , Erica Shane , Benjamin S. Isaacs , Christian B. Allan , Stephen T. Chang
发明人： Cynthia N. OLIVER , Erica Shane , Benjamin S. Isaacs , Christian B. Allan , Stephen T. Chang
IPC分类号： A61K39/42 , A61P31/14
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译：本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，并且极少数或不损失生物 SYNAGIS®或其抗原结合片段的活性，甚至在长时间的储存期间。特别地，本发明提供了免疫特异性结合RSV抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。

3. 发明授权

US07785592B2 Stabilized liquid anti-RSV antibody formulations 有权
标题翻译：稳定液体抗RSV抗体制剂
公开(公告)号：US07785592B2
公开(公告)日：2010-08-31
申请号：US11906543
申请日：2007-10-01
申请人： Cynthia N. Oliver , Erica Shane , Benjamin S. Isaacs , Christian B. Allan , Stephen T. Chang
发明人： Cynthia N. Oliver , Erica Shane , Benjamin S. Isaacs , Christian B. Allan , Stephen T. Chang
IPC分类号： A61K39/395 , A61K39/40 , A61K39/42 , C07K16/00
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译：本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，并且极少数或不损失生物 SYNAGIS®或其抗原结合片段的活性，甚至在长时间的储存期间。特别地，本发明提供了免疫特异性结合RSV抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。

4. 发明申请

US20090175883A1 Stabilized anti-respiratory syncytial virus (RSV) antibody formulations 审中-公开
标题翻译：稳定的抗呼吸道合胞病毒（RSV）抗体制剂
公开(公告)号：US20090175883A1
公开(公告)日：2009-07-09
申请号：US12075197
申请日：2008-03-10
申请人： Cynthia N. Oliver , Christian B. Allan , Stephen T. Chang
发明人： Cynthia N. Oliver , Christian B. Allan , Stephen T. Chang
IPC分类号： A61K39/395 , A61P31/12
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K2039/505 , C07K2317/56 , C07K2317/565 , A61K2300/00
摘要： The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.
摘要翻译：本发明提供免疫特异性结合呼吸道合胞病毒（RSV）抗原的抗体或其片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，以及抗体的生物活性几乎至不损失，或抗体片段，即使在长时间的储存期间。特别地，本发明提供免疫特异性结合RSV抗原的抗体或其片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的一种或多种症状的方法。

5. 发明申请

US20080286270A1 Stabilized liquid anti-RSV antibody formulations 有权
标题翻译：稳定液体抗RSV抗体制剂
公开(公告)号：US20080286270A1
公开(公告)日：2008-11-20
申请号：US11906543
申请日：2007-10-01
申请人： Cynthia N. Oliver , Erica Shane , Benjamin S. Isaacs , Christian B. Allan , Stephen T. Chang
发明人： Cynthia N. Oliver , Erica Shane , Benjamin S. Isaacs , Christian B. Allan , Stephen T. Chang
IPC分类号： A61K39/395 , A61P11/00
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译：本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，以及很少甚至没有损失 SYNAGIS或其抗原结合片段的生物活性，甚至在长时间的储存期间。特别地，本发明提供了SYNAGIS或其抗原结合片段的液体制剂，其免疫特异性结合RSV抗原，该制剂基本上不含表面活性剂，无机盐和/或其它常见赋形剂。此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。

6. 发明授权

US07425618B2 Stabilized anti-respiratory syncytial virus (RSV) antibody formulations 有权
标题翻译：稳定的抗呼吸道合胞病毒（RSV）抗体制剂
公开(公告)号：US07425618B2
公开(公告)日：2008-09-16
申请号：US10461863
申请日：2003-06-13
申请人： Cynthia N. Oliver , Christian B. Allan , Stephen T. Chang
发明人： Cynthia N. Oliver , Christian B. Allan , Stephen T. Chang
IPC分类号： C12P21/08
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K2039/505 , C07K2317/56 , C07K2317/565 , A61K2300/00
摘要： The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.
摘要翻译：本发明提供免疫特异性结合呼吸道合胞病毒（RSV）抗原的抗体或其片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，以及抗体的生物活性几乎至不损失，或抗体片段，即使在长时间的储存期间。特别地，本发明提供免疫特异性结合RSV抗原的抗体或其片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的一种或多种症状的方法。

7. 发明授权

US06478134B2 High speed manufacturing system 有权
标题翻译：高速制造系统
公开(公告)号：US06478134B2
公开(公告)日：2002-11-12
申请号：US09815319
申请日：2001-03-22
申请人： Imre A. Pattantyus-Abraham , Chad E. Law , Patrick J. Weber , Stanley W. Stedman , Stephen T. Chang
发明人： Imre A. Pattantyus-Abraham , Chad E. Law , Patrick J. Weber , Stanley W. Stedman , Stephen T. Chang
IPC分类号： B65G1526
CPC分类号： B65G47/5122 , B65G37/02 , B65G2203/025
摘要： A high speed manufacturing system for processing articles of manufacture requiring processes to be performed on the articles at a pre-selected processing rate includes a trunk for simultaneously conveying a plurality of the articles of manufacture at the pre-selected processing rate in a first mode of motion from the beginning of the manufacturing system to the end of the system. At least one branch processing station is positioned intermediate the beginning and the end of the trunk wherein the branch processing station during its operation performs at least one process on articles of manufacture conveyed on the branch processing station and where the articles are conveyed in a second mode of motion. At least one transfer device is positioned intermediate the trunk and the branch processing station to continuously extract articles of manufacture from the trunk and transition the movement of the extracted articles of manufacture from the first mode of motion to the second mode of motion for transfer to the branch processing station. The transfer device also extracts each of the processed articles of manufacture from the branch processing station and transitions the movement of the articles from the second mode of motion to the first mode of motion for transfer to the trunk.
摘要翻译：用于处理制品的高速制造系统要求以预先选择的处理速率在物品上执行处理，包括用于以预先选择的处理速率在第一模式中同时传送多个制品的主干从制造系统开始到系统结束的运动。至少一个分支处理站位于干线的开始和结束之间，其中分支处理站在其操作期间对在分支处理站上传送的制品进行至少一个处理，并且以第二模式传送物品的运动。至少一个传送设备位于中继线和分支处理站之间，以连续地从主干提取制品，并将提取的制品的运动从第一运动模式转移到第二运动模式，以转移到分支处理站。传送设备还从分支处理站中提取每个处理过的制品，并且将物品从第二运动模式移动到第一移动模式以转移到主干。

8. 发明授权

US08460663B2 Stabilized liquid anti-RSV antibody formulations 有权
公开(公告)号：US08460663B2
公开(公告)日：2013-06-11
申请号：US13481640
申请日：2012-05-25
申请人： Cynthia N. Oliver , Erica Shane , Benjamin S. Isaacs , Christian B. Allan , Stephen T. Chang
发明人： Cynthia N. Oliver , Erica Shane , Benjamin S. Isaacs , Christian B. Allan , Stephen T. Chang
IPC分类号： A61K39/395 , A61K39/42
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

9. 发明授权

US08007793B2 Stabilized liquid anti-RSV antibody formulations 有权
标题翻译：稳定液体抗RSV抗体制剂
公开(公告)号：US08007793B2
公开(公告)日：2011-08-30
申请号：US12817097
申请日：2010-06-16
申请人： Cynthia N. Oliver , Erica Shane , Benjamin S. Isaacs , Christian B. Allan , Stephen T. Chang
发明人： Cynthia N. Oliver , Erica Shane , Benjamin S. Isaacs , Christian B. Allan , Stephen T. Chang
IPC分类号： A61K39/395 , A61K39/42
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译：本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，并且极少数或不损失生物 SYNAGIS®或其抗原结合片段的活性，甚至在长时间的储存期间。特别地，本发明提供了免疫特异性结合RSV抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。

10. 发明申请

US20110027272A1 STABILIZED LIQUID ANTI-RSV ANTIBODY FORMULATIONS 有权
标题翻译：稳定液体抗RSV抗体制剂
公开(公告)号：US20110027272A1
公开(公告)日：2011-02-03
申请号：US12817097
申请日：2010-06-16
申请人： Cynthia N. OLIVER , Erica Shane , Benjamin S. Isaacs , Christian B. Allan , Stephen T. Chang
发明人： Cynthia N. OLIVER , Erica Shane , Benjamin S. Isaacs , Christian B. Allan , Stephen T. Chang
IPC分类号： A61K39/395 , A61P37/04 , A61P31/12
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译：本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，并且极少数或不损失生物 SYNAGIS®或其抗原结合片段的活性，甚至在长时间的储存期间。特别地，本发明提供了免疫特异性结合RSV抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式